Thursday, August 11, 2011
Adolor Corp., of Exton, Pa., reported top-line data from two randomized, double-blind, placebo-controlled Phase II trials of ADL5945 for opioid-induced constipation. When dosed twice daily, high-dose ADL5945 significantly increased the weekly number of spontaneous bowel movements vs. placebo (3.4 SBMs vs. 1.4 SBMs; p = 0.0003).
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.